AET BioTech and BioXpress Therapeutics to Co-Develop Biosimilar Adalimumab

AET BioTech and BioXpress Therapeutics to Co-Develop Biosimilar Adalimumab PR Newswire GZIRA, Malta, HAMBURG, Germany and GENEVA, October 30, 2012 GZIRA, Malta, HAMBURG, Germany and GENEVA, October 30, 2012 /PRNewswire/ -- AET BioTech, the separate biosimilars business within the generic drug developer AET (Alfred E Tiefenbacher) Group and BioXpress Therapeutics SA, a Swiss-based biotechnology company developing monoclonal antibody (MAb) biosimilars have entered into an agreement for the co-development of a biosimilar version of the TNF inhibitor MAb Adalimumab. AET BioTech and BioXpress will be jointly responsible for the development, registration, and manufacture of the biosimilar, which is based on BioXpress technology. The development strategy devised and implemented by the partners incorporates regulatory requirements for marketing in countries worldwide. Beside active involvement in the development of the MAb, AET BioTech will in particular be responsible for providing further investment in the biosimilar based on committed long term financing. AET BioTech is also responsible for any future commercialisation of the product. Adalimumab as currently marketed by Abbott had 2011 global sales exceeding $7.9 billion USD.